Incyte Corp (NASDAQ:INCY)

85.51
Delayed Data
As of Feb 20
 -0.52 / -0.60%
Today’s Change
80.85
Today|||52-Week Range
153.15
-9.71%
Year-to-Date
Get Rid of 5 Toxic Stocks or Sell Short for Profit
Feb 19 / Zacks.com - Paid Partner Content
Why Incyte (INCY) Might Surprise This Earnings Season
Feb 14 / Zacks.com - Paid Partner Content
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales
Feb 15 / Zacks.com - Paid Partner Content
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
Feb 12 / Zacks.com - Paid Partner Content
Incyte (INCY) Beats on Sales in Q4
Feb 15 / Zacks.com - Paid Partner Content
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
Feb 09 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close86.03
Today’s open85.60
Day’s range84.58 - 87.56
Volume1,357,429
Average volume (3 months)1,718,344
Market cap$18.2B
Data as of 4:00pm ET, 02/20/2018

Growth & Valuation

Earnings growth (last year)-383.33%
Earnings growth (this year)--
Earnings growth (next 5 years)+57.90%
Revenue growth (last year)+38.93%
P/E ratioNM
Price/Sales12.61
Price/Book11.15

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+0.62+0.78%
ALXNAlexion Pharmaceutic...-1.62-1.34%
BAXBaxter International...+0.71+1.07%
MYLMylan NV-0.80-1.90%
Data as of 4:15pm ET, 02/20/2018

Financials

Last reporting dateFebruary 15, 2018
EPS forecast (this quarter)-$0.48
Annual revenue (last year)$1.5B
Annual profit (last year)-$313.1M
Net profit margin-20.38%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts